- •PK based tailoring of prophylaxis in hemophilia was proposed to 39 Japanese patients.
- •Dose increase, infusion frequency reduction, or switch to extended half-life concentrates can explain.
- •Adherence to treatment improved or did not change.
- •The annualized bleeding improved or remained unchanged, and was associated with time spent above 0.01 or 0.05 IU/mL.
Abbreviations:PK (pharmacokinetic), SHL (standard half-life products), EHL (extended half-life products), rFVIII (recombinant factor VIII), FVIII:C (FVIII activity), ABR (annualized bleeding rate), AjBR (annualized joint bleeding rate)
- Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.Haemophilia. 2011; 17: 2-10
- Focusing in on use of pharmacokinetic profiles in routine hemophilia care.Res. Pract. Thromb. Haemost. 2018; 27: 607-614
- The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors.2001: 1-9 (Available from:)
- Development of a web-accessible population pharmacokinetic service—hemophilia (WAPPS-Hemo): study protocol.JMIR Res. Protoc. 2016; 5 ([Internet]. Available from:): e239
- Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A.Haemophilia. 2010; 16: 597-605
- Definitions in hemophilia: communication from the SSC of the ISTH.J. Thromb. Haemost. 2014; 12: 1935-1939
- Hemophilic arthropathy. Current concepts of pathogenesis and management.J. Bone Joint Surg. Am. 1977; 59: 287-305
- Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.Haemophilia. 2015; 21: 458-464
- Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study.Br. J. Haematol. 2016; 174: 454-460
- Objective quantification of adherence to prophylaxis in haemophilia patients aged 12 to 25 years and its potential association with bleeding episodes.Thromb. Res. 2016; 143 ([Internet] Elsevier Ltd.. Available from): 22-27